Additionally, we observed a significantly higher expression of activation molecules, namely, HLA-ABC, HLA-DR, CD86 and CD40, in TIL-Bs derived from tumor samples with high levels of B cells in comparison to TIL-Bs derived from Blo (< 5% of total cells) samples. This evidence concerns the gene CD86 and neoplasm.